Article
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Nov 2020
Salama April K S, Li Shuli, Macrae Erin R, Park Jong-In, Mitchell Edith P, Zwiebel James A, Chen Helen X, Gray Robert J, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Armstrong Deborah K, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T
Abstract excerpt
PURPOSE: BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored a BRAFV600 mutation. PATIENTS AND METHODS: EAY131-H...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.